Co-ordinate transcriptional regulation of dopamine synthesis genes by α-synuclein in human neuroblastoma cell lines

Journal of Neurochemistry

Volumn 85, Issue 4, 2003, Pages 957-968

  Baptista, Melisa J ^a   O'Farrell, Casey ^b   Daya, Sneha ^a   Ahmad, Rili ^a   Miller, David W ^a   Hardy, John ^a   Farrer, Matthew J ^b   Cookson, Mark R ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Oligonucleotide expression array; Parkinson's disease; Quantitative real time RT PCR; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AROMATIC ACID DECARBOXYLASE; CARBOXYLYASE; DIHYDROPTERIDINE REDUCTASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; MESSENGER RNA; SEPIAPTERIN REDUCTASE; TRANSCRIPTION FACTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; DNA MICROARRAY; DOPAMINE METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

EID: 0038701729     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01742.x     Document Type: Article

References (58)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W. H., Castillo P. E., Shinsky N., Verdugo J. M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D. and Rosenthal A. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Agneter E., Sitte H. H., Stockl-Hiesleitner S., Fischer-Colbrie R., Winkler H. and Singer E. A. (1995) Sustained dopamine release induced by secretoneurin in the striatum of the rat: a microdialysis study. J. Neurochem. 65, 622-625.
3. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
4. Bostantjopoulou S., Katsarou Z., Papadimitriou A., Veletza V., Hatzigeorgiou G. and Lees A. (2001) Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Movement Disorders 16, 1007-1013.
5. Braak H. and Braak E. (2000) Pathoanatomy of Parkinson's disease. J. Neurol. 247, 3-10.
6. Brosenitsch T. A. and Katz D. M. (2001) Physiological patterns of electrical stimulation can induce neuronal gene expression by activating N-type calcium channels. J. Neurosci. 21, 2571-2579.
7. Cabin D. E., Shimazu K., Murphy D., Cole N. B., Gottschalk W., Mcllwain K. L., Orrison B., Chen A., Ellis C. E., Paylor R., Lu B. and Nussbaum R. L. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797-8807.
8. Chu Y., Kompoliti K., Cochran E. J., Mufson E. J. and Kordower J. H. (2002) Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J. Comp. Neurol. 450, 203-214.
9. Ciccarone V., Spengler B., Meyers J., Biedler J. and Ross R. (1989) Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res. 49, 219-225.
10. Conway K. A., Harper J. D. and Lansbury P. T. (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563.
11. Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349.
12. Dickson D. W. (2001) alpha-Synuclein and the Lewy body disorders. Curr. Opin. Neurol. 14, 423-432.
13. Farrer M., Maraganore D. M., Lockhart P., Singleton A., Lesnick T. G., de Andrade M., West A., de Silva R., Hardy J. and Hernandez D. (2001) alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10, 1847-1851.
14. Feany M. B. and Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
15. Gomez-Santos C., Ferrer I., Reiriz J., Vinals F., Barrachina M. and Ambrosio S. (2002) MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res. 935, 32-39.
16. Grunblatt E., Mandel S., Maor G. and Youdim M. B. (2001) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78, 1-12.
17. Iwata A., Maruyama M., Kanazawa I. and Nukina N. (2001a) alpha-Synuclein affects the MAPK pathway and accelerates cell death. J. Biol. Chem. 276, 45320-45329.
18. Iwata A., Miura S., Kanazawa I., Sawada M. and Nukina N. (2001b) alpha-Synuclein forms a complex with transcription factor Elk-1. J. Neurochem. 77, 239-252.
19. Kennan A., Aherne A., Palfi A., Humphries M., McKee A., Stitt A., Simpson D. A., Demtroder K., Omtoft T., Ayuso C., Kenna P. F., Farrar G. J. and Humphries P. (2002) Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho-/- mice. Hum. Mol. Genet. 11, 547-557.
20. Khatri P., Draghici S., Ostermeier G. C. and Krawetz S. A. (2002) Profiling gene expression using onto-express. Genomics 79, 266-270.
21. Ko L., Mehta N. D., Farrer M., Easson C., Hussey J., Yen S., Hardy J. and Yen S. H. (2000) Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J. Neurochem. 75, 2546-2554.
22. Kovalovsky D., Refojo D., Liberman A. C., Hochbaum D., Pereda M. P., Coso O. A., Stalla G. K., Holsboer F. and Arzt E. (2002) Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol. 16, 1638-1651.
23. Kowall N. W., Hantraye P., Brouillet E., Beal M. F., McKee A. C. and Ferrante R. J. (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211-213.
24. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
25. Le W. D., Xu P., Jankovic J., Jiang H., Appel S. H., Smith R. G. and Vassilatis D. K. (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33, 85-89.
26. Lee F. J., Liu F., Pristupa Z. B. and Niznik H. B. (2001a) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926.
27. Lee H. J., Shin S. Y., Choi C., Lee Y. H. and Lee S. J. (2001b) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277, 5411-5417.
28. Lehmensiek V., Tan E. M., Schwarz J. and Storch A. (2002) Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. Neuroreport 13, 1279-1283.
29. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H. K. and Brundin P. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38884-38894.
30. Marsden C. D. (1994) Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57, 672-681.
31. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
32. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W. J., McGowan E., Farrer M., Hardy J., Duff K., Przedborski S. and Di Monte D. A. (2001) Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535-539.
33. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H. and Nagatsu T. (2000) Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J. Neural Transm. 107, 335-341.
34. Mouradian M. M. (2002) Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58, 179-185.
35. Murphy D. D., Rueter S. M., Trojanowski J. Q. and Lee V. M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220.
36. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J. M., Farrer M. and Wolozin B. (2000) The A53T α-synuclein mutation increases irondependant aggregation and toxicity. J. Neurosci. 20, 6048-6054.
37. Perez R. G., Waymire J. C., Lin E., Liu J. J., Guo F. and Zigmond M. J. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099.
38. Petrucelli L., O'Farrell C., Lockhart P. J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J. and Cookson M. R. (2002) Parkin protects against the toxicity associated with overexpression of mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007-1019.
39. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E. S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W. G., Lazzarini A. M., Duvoisin R. C., Di Iorio G., Golbe L. I. and Nussbaum R. L. (1997) Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
40. Pomeroy S. L., Tamayo P., Gaasenbeek M., Sturla L. M., Angelo M., McLaughlin M. E., Kim J. Y., Goumnerova L. C., Black P. M., Lau C., Allen J. C., Zagzag D., Olson J. M., Curran T., Wetmore C., Biegel J. A., Poggio T., Mukherjee S., Rifkin R., Califano A., Stolovitzky G., Louis D. N., Mesirov J. P., Lander E. S. and Golub T. R. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442.
41. Przedborski S., Chen Q., Vila M., Giasson B. I., Djaldatti R., Vukosavic S., Souza J. M., Jackson-Lewis V., Lee V. M. and Ischiropoulos H. (2001) Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76, 637-640.
42. Rajeevan M. S., Ranamukhaarachchi D. G., Vernon S. D. and Unger E. R. (2001) Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies. Methods Dec 25(4), 443-451.
43. Ramaswamy S., Tamayo P., Rifkin R., Mukherjee S., Yeang C. H., Angelo M., Ladd C., Reich M., Latulippe E., Mesirov J. P., Poggio T., Gerald W., Loda M., Lander E. S. and Golub T. R. (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA 98, 15149-15154.
44. Sakurada K., Ohshima-Sakurada M., Palmer T. D. and Gage F. H. (1999) Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126, 4017-4026.
45. Saria A., Troger J., Kirchmair R., Fischer-Colbrie R., Hogue-Angeletti R. and Winkler H. (1993) Secretoneurin releases dopamine from rat striatal slices: a biological effect of a peptide derived from secretogranin II (chromogranin C). Neuroscience 54, 1-4.
46. Sherer T. B., Betarbet R., Stout A. K., Lund S., Baptista M., Panov A. V., Cookson M. R. and Greenamyre J. T. (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22, 7006-7015.
47. Skipper L. and Farrer M. (2002) Parkinson's genetics: Molecular insights for the new millenium. Neurotoxicology Oct; 23(4-5), 503-514.
48. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) alpha-Synuclein in Lewy bodies. Nature 388, 839-840.
49. Spira P. J., Sharpe D. M., Halliday G., Cavanagh J. and Nicholson G. A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313-319.
50. Stefanis L., Larsen K. E., Rideout H. J., Sulzer D. and Greene L. A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549-9560.
51. Tanaka Y., Engelender S., Igarashi S., Rao R. K., Wanner T., Tanzi R. E., Sawa A. L., Dawson V., Dawson T. M. and Ross C. A. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919-926.
52. Tomkinson B. (1999) Tripeptidyl peptidases: enzymes that count. Trends Biochem. Sci. 24, 355-359.
53. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M. and Przedborski S. (2000) alpha-Synuclein up-regulation in substantia nigra dopammergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721-729.
54. Westphal C. H., Muller L., Zhou A., Zhu X., Bonner-Weir S., Schambelan M., Steiner D. F., Lindberg I. and Leder P. (1999) The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 96, 689-700.
55. Xu J., Kao S.-Y., Lee F. J. S., Song W., Jin L.-W. and Yankner B. A. (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606.
56. Yoshihara T., Ishigaki S., Yamamoto M., Liang Y., Niwa J., Takeuchi H., Doyu M. and Sobue G. (2002) Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 80, 158-167.
57. Zhou W., Hurlbert M. S., Schaack J., Prasad K. N. and Freed C. R. (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866, 33-43.
58. Zirlinger M., Kreiman G. and Anderson D. J. (2001) Amygdala-enriched genes identified by microarray technology are restricted to specific amygdaloid subnuclei. Proc. Natl Acad. Sci. USA 98, 5270-5275.